OSTEOARTHRITIS
Orally administered curcumin for the treatment of knee osteoarthritis
J Orthop Sci. 2014 Nov;19(6):933-950 patients with knee primary osteoarthritis were randomly assigned to receive orally administered 180 mg/day curcumin (Theracurmin) or placebo for 8 weeks. The purpose of this trial was to determine the effects of curcumin in patients with knee osteoarthritis via blood biochemistry analyses, VAS pain, Japanese Knee Osteoarthritis Measure, Japanese Orthopedic Association knee scoring system, need for nonsteroidal anti-inflammatory drugs (NSAIDs), and adverse events. The findings revealed similar outcomes between groups at final follow-up, however, fewer patients in the curcumin group required additional NSAID analgesia than in the placebo group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
